Excela Health Latrobe Hospital | |
One Mellon Way, Latrobe, Pennsylvania 15650 | |
(724) 537-1000 | |
Name | Excela Health Latrobe Hospital |
---|---|
Type | Acute Care Hospital |
Location | One Mellon Way, Latrobe, Pennsylvania |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 390219 |
NPI Number | 1265649776 |
Organization Name | EXCELA HEALTH LATROBE HOSPITAL |
Doing Business As | WOMEN'S CARE SERVICE |
Address | 212 W 2nd Ave, Latrobe, PA 15650 |
Hospital Type | General Acute Care Hospital - Rural |
Phone Number | 724-537-1870 |
News Archive
The intestinal bacterium Akkermansia proves to offer enduring benefits for the intestines of overweight mice and diabetic animals.
Timing is everything when it comes to the development of the vertebrate face. In a new study published in PLoS Genetics, USC Stem Cell researcher Lindsey Barske from the laboratory of Gage Crump and her colleagues identify the roles of key molecular signals that control this critical timing.
Labopharm Inc. today announced that it has further reduced its workforce, eliminating 23 positions. Following the reduction, Labopharm will have 71 employees to support its continuing operations.
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).
› Verified 9 days ago
NPI Number | 1689673550 |
Organization Name | SELECT SPECIALTY HOSPITAL - LAUREL HIGHLANDS INC |
Address | One Mellon Way, 3rd Floor, Latrobe, PA 15650 |
Hospital Type | Long Term Care Hospital |
Phone Number | 724-830-8649 |
News Archive
The intestinal bacterium Akkermansia proves to offer enduring benefits for the intestines of overweight mice and diabetic animals.
Timing is everything when it comes to the development of the vertebrate face. In a new study published in PLoS Genetics, USC Stem Cell researcher Lindsey Barske from the laboratory of Gage Crump and her colleagues identify the roles of key molecular signals that control this critical timing.
Labopharm Inc. today announced that it has further reduced its workforce, eliminating 23 positions. Following the reduction, Labopharm will have 71 employees to support its continuing operations.
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).
› Verified 9 days ago
NPI Number | 1821015462 |
Organization Name | LATROBE AREA HOSPITAL, INC. |
Address | 121 W 2nd Ave, Latrobe, PA 15650 |
Hospital Type | General Acute Care Hospital |
Phone Number | 724-537-1000 |
News Archive
The intestinal bacterium Akkermansia proves to offer enduring benefits for the intestines of overweight mice and diabetic animals.
Timing is everything when it comes to the development of the vertebrate face. In a new study published in PLoS Genetics, USC Stem Cell researcher Lindsey Barske from the laboratory of Gage Crump and her colleagues identify the roles of key molecular signals that control this critical timing.
Labopharm Inc. today announced that it has further reduced its workforce, eliminating 23 positions. Following the reduction, Labopharm will have 71 employees to support its continuing operations.
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).
› Verified 9 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
The intestinal bacterium Akkermansia proves to offer enduring benefits for the intestines of overweight mice and diabetic animals.
Timing is everything when it comes to the development of the vertebrate face. In a new study published in PLoS Genetics, USC Stem Cell researcher Lindsey Barske from the laboratory of Gage Crump and her colleagues identify the roles of key molecular signals that control this critical timing.
Labopharm Inc. today announced that it has further reduced its workforce, eliminating 23 positions. Following the reduction, Labopharm will have 71 employees to support its continuing operations.
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months. The study, published today in the American Journal of Transplantation, provides the first findings to come from BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial).
› Verified 9 days ago
Excela Health Latrobe Hospital Acute Care Hospital Location: One Mellon Way, Latrobe, Pennsylvania 15650 Phone: (724) 537-1000 |